Abstract
Cyclin B1, a mitotic cyclin, has been implicated in malignances. However, its contribution to colorectal cancer invasion and metastasis are still not well understood. Here, we demonstrated that the invasion and metastasis of colorectal cancer is regulated by Cyclin B1. Overexpression of Cyclin B1 was observed in colorectal cancer tissues, but this elevated expression was negatively associated with lymph node metastasis, distant metastasis stage, and TNM stage. The Kaplan-Meier survival analysis proved that low Cyclin B1 expression was associated with poor overall survival of patients with colorectal cancer. Inhibition of Cyclin B1 in colorectal cancer cells enhanced the cell migration and invasion of three different colorectal cancer cell lines. In studying the possible mechanism by which Cyclin B1 suppresses colorectal cancer invasion and metastasis, we observed that suppression of Cyclin B1 decreased the expression of E-cadherin protein level. Our findings suggest that Cyclin B1 could suppress the invasion and metastasis of colorectal cancer cells through regulating E-cadherin expression, which enables the development of potential intervention strategies for colorectal cancer.
Highlights
Despite increased general awareness, colorectal cancer remains one of the three leading causes of malignancy-related mortality worldwide [1]
To identify the potential role of Cyclin B1 in colorectal cancer metastasis, we initially examined the expression of Cyclin B1 in 150 pairs of colorectal cancers and matched adjacent non-tumor colorectal tissues using qRT-PCR
We showed that Cyclin B1 suppressed colorectal cancer invasion and metastasis through regulation of E-cadherin expression
Summary
Colorectal cancer remains one of the three leading causes of malignancy-related mortality worldwide [1]. The majority of the colorectal cancer patients in the early stage (TNM stage I and II) can be treated effectively by surgical resection and the 5-year survival rates for the early stage cancers is up to 95% (stage I) and 60–80% (stage II), respectively. Most patients with metastatic colorectal cancer in the advanced stage (TNM stage III and IV) are usually refractory to existing therapies and have quite a poor prognosis since the 5-year survival rates drop dramatically to 35% with lymph node involvement (stage III) and to 10% when the disease has spread to distant organs (stage IV) [2,3,4,5]. PLOS ONE | DOI:10.1371/journal.pone.0126875 May 11, 2015
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call